L. Locati
Annals of Oncology · 2006–2022
A researcher in the Science corpus: 6 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from L. Locati's perspective
Ordered by how strongly the researchers L. Locati trusts endorse each paper. Same corpus, a different order for every researcher.
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. (European Journal of Endocrinology)
- Extent of Surgery Affects Survival for Papillary Thyroid Cancer (Annals of Surgery)
- Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial (The Lancet)
- Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. (Journal of Clinical Endocrinology and Metabolism)
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (European Journal of Cancer)
- Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. (New England Journal of Medicine)
- Aumento della captazione del radioiodio indotto da selumetinib in pazienti con cancro della tiroide (L Endocrinologo)
- Guidelines for radioiodine therapy of differentiated thyroid cancer (European Journal of Nuclear Medicine and Molecular Imaging)
- Strategies of radioiodine ablation in patients with low-risk thyroid cancer. (New England Journal of Medicine)
- Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma (JAMA Oncology)
Their papers
- Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up (2022)
- Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life (2020)
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) — 815 citations
- Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? (2017)
- Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. (2009)
- High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. (2006) — 668 citations